Cipher Pharmaceuticals Inc. (TSX:CPH)
17.99
+0.44 (2.51%)
Aug 10, 2026, 3:59 PM EST
Cipher Pharmaceuticals Revenue
Cipher Pharmaceuticals had revenue of $12.51M USD in the quarter ending March 31, 2026, with 4.04% growth. This brings the company's revenue in the last twelve months to $50.94M, up 28.91% year-over-year. In the year 2025, Cipher Pharmaceuticals had annual revenue of $50.45M with 51.22% growth.
Revenue (ttm)
$50.94M
Revenue Growth
+28.91%
P/S Ratio
6.28
Revenue / Employee
$10.19M
Employees
5
Market Cap
446.54M CAD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 50.45M | 17.09M | 51.22% |
| Dec 31, 2024 | 33.36M | 12.20M | 57.66% |
| Dec 31, 2023 | 21.16M | 487.00K | 2.36% |
| Dec 31, 2022 | 20.68M | -1.27M | -5.78% |
| Dec 31, 2021 | 21.94M | 336.00K | 1.56% |
| Dec 31, 2020 | 21.61M | -844.00K | -3.76% |
| Dec 31, 2019 | 22.45M | -298.00K | -1.31% |
| Dec 31, 2018 | 22.75M | -17.39M | -43.33% |
| Dec 31, 2017 | 40.14M | 10.49M | 35.38% |
| Dec 31, 2016 | 29.65M | -4.76M | -13.83% |
| Dec 31, 2015 | 34.41M | 5.19M | 17.74% |
| Dec 31, 2014 | 29.22M | 3.83M | 15.08% |
| Dec 31, 2013 | 25.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Verano Holdings | 1.19B |
| Cresco Labs | 921.13M |
| Knight Therapeutics | 547.31M |
| TerrAscend | 374.77M |
| Aurora Cannabis | 314.07M |
| Canopy Growth | 293.63M |
| DRI Healthcare Trust | 284.88M |
| Organigram Global | 274.19M |
Cipher Pharmaceuticals News
- 3 months ago - Cipher Pharmaceuticals price target raised to C$22 from C$21 at Stifel - TheFly
- 3 months ago - Cipher Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 3 months ago - Cipher Pharmaceuticals Slides: Q1 2026 - Filings
- 3 months ago - Cipher Pharmaceuticals Earnings release: Q1 2026 - Filings
- 3 months ago - Cipher Pharmaceuticals Registration statement: Q1 2026 - Filings
- 3 months ago - Cipher Pharmaceuticals Registration statement: Q1 2026 - Filings
- 4 months ago - CaryHealth launches direct-to-patient program for Cipher’s Natroba - TheFly
- 4 months ago - CaryHealth Launches Direct-to-Patient Program for Cipher Pharmaceuticals' Natroba™ (spinosad) - Business Wire